Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 40kWORD 9k
11 March 2020
Question for written answer E-001545/2020
to the Commission
Rule 138
Alex Agius Saliba (S&D)
 Answer in writing 
 Subject: Myalgic encephalomyelitis/chronic fatigue syndrome

Living with myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS) can be very difficult. Extreme tiredness and other physical symptoms can make carrying out everyday activities difficult and can affect a patient’s mental and emotional health.

Therefore, it is important to address the human and socio-economic consequences linked to the rising number of individuals living and working with these long-term disabling chronic conditions. These conditions have an impact on the sustainability and continuity of a patient’s work and employment.

1. Can the Commission clarify whether it will allocate additional funding and prioritise calls for proposals focusing on biomedical research into ME/CFS that aim to develop and validate a biomedical diagnostic test and effective biomedical treatments to cure or alleviate the effects of the disease?

2. What is it doing to foster cooperation and the exchange of best practices among the Member States as regards screening methods, diagnoses and treatments?

3. What steps is it taking to create an EU prevalence register of patients affected by ME/CFS?

Last updated: 25 September 2020Legal notice - Privacy policy